Protara Therapeutics (TARA) Competitors $5.17 +0.02 (+0.39%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TARA vs. SIGA, ORGO, KALV, KRRO, CDXC, TKNO, ALMS, AURA, AKBA, and IGMSShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include SIGA Technologies (SIGA), Organogenesis (ORGO), KalVista Pharmaceuticals (KALV), Korro Bio (KRRO), ChromaDex (CDXC), Alpha Teknova (TKNO), Alumis (ALMS), Aura Biosciences (AURA), Akebia Therapeutics (AKBA), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. SIGA Technologies Organogenesis KalVista Pharmaceuticals Korro Bio ChromaDex Alpha Teknova Alumis Aura Biosciences Akebia Therapeutics IGM Biosciences Protara Therapeutics (NASDAQ:TARA) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Do analysts rate TARA or SIGA? Protara Therapeutics presently has a consensus price target of $22.67, suggesting a potential upside of 338.43%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than SIGA Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00SIGA Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, TARA or SIGA? SIGA Technologies has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$40.42M-$2.82-1.83SIGA Technologies$173.73M2.47$68.07M$1.205.00 Does the MarketBeat Community favor TARA or SIGA? Protara Therapeutics received 31 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 66.67% of users gave Protara Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote. CompanyUnderperformOutperformProtara TherapeuticsOutperform Votes3666.67% Underperform Votes1833.33% SIGA TechnologiesOutperform Votes523.81% Underperform Votes1676.19% Does the media favor TARA or SIGA? In the previous week, SIGA Technologies had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 1 mentions for SIGA Technologies and 0 mentions for Protara Therapeutics. SIGA Technologies' average media sentiment score of 1.11 beat Protara Therapeutics' score of 0.00 indicating that SIGA Technologies is being referred to more favorably in the news media. Company Overall Sentiment Protara Therapeutics Neutral SIGA Technologies Positive Do insiders & institutionals believe in TARA or SIGA? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by company insiders. Comparatively, 1.5% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is TARA or SIGA more profitable? SIGA Technologies has a net margin of 49.33% compared to Protara Therapeutics' net margin of 0.00%. SIGA Technologies' return on equity of 49.06% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -55.96% -49.06% SIGA Technologies 49.33%49.06%38.72% Which has more volatility and risk, TARA or SIGA? Protara Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. SummarySIGA Technologies beats Protara Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Insiders ExposedMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.👉 Click here now to see how this signal works. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.66M$2.96B$5.24B$9.28BDividend YieldN/A1.91%5.12%4.28%P/E Ratio-1.8345.6887.7717.30Price / SalesN/A420.391,170.81120.32Price / CashN/A174.7643.2337.83Price / Book0.863.924.834.94Net Income-$40.42M-$42.00M$120.76M$225.76M7 Day Performance0.19%3.87%2.91%4.17%1 Month Performance98.85%-0.23%19.76%1.19%1 Year Performance182.51%18.83%30.62%17.08% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics2.0746 of 5 stars$5.17+0.4%$22.67+338.4%+182.5%$106.66MN/A-1.8330SIGASIGA Technologies1.9109 of 5 stars$5.94+0.5%N/A+5.3%$424.15M$173.73M4.9540Positive NewsORGOOrganogenesis4.2628 of 5 stars$3.19+4.6%$5.33+67.2%-19.7%$422.92M$455.04M-53.17950KALVKalVista Pharmaceuticals4.0419 of 5 stars$8.46+1.2%$23.33+175.8%-25.0%$418.08MN/A-2.32150KRROKorro Bio1.6892 of 5 stars$43.76+0.2%$142.17+224.9%-14.3%$409.94M$14.07M0.0070CDXCChromaDex4.6321 of 5 stars$5.36-2.4%$8.00+49.3%+275.2%$409.41M$91.67M536.54106Analyst UpgradeNews CoverageTKNOAlpha Teknova0.9807 of 5 stars$7.66-0.9%$5.00-34.7%+159.8%$408.34M$36.35M-10.35240News CoverageGap UpALMSAlumisN/A$8.63-2.2%$26.83+210.9%N/A$407.53MN/A0.00N/ALockup ExpirationAURAAura Biosciences2.5223 of 5 stars$8.14-0.7%$23.00+182.6%-5.6%$406.60MN/A-4.7150Positive NewsAKBAAkebia Therapeutics3.612 of 5 stars$1.84+0.5%$7.50+307.6%+56.3%$401.45M$169.88M-8.00167IGMSIGM Biosciences4.5844 of 5 stars$6.48-6.1%$17.75+173.9%-23.4%$385.33M$2.92M-1.78190 Related Companies and Tools Related Companies SIGA Alternatives ORGO Alternatives KALV Alternatives KRRO Alternatives CDXC Alternatives TKNO Alternatives ALMS Alternatives AURA Alternatives AKBA Alternatives IGMS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TARA) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
